Conditions: Diabetes Mellitus, Type 2
Keywords: diabetes mellitus, type 2 nateglinide acarbose hyperglycemia dyslipidemias C-reactive protein
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 160
Healthy volunteers: no

Brief summary:
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.

Detailed description:

Arms:
arm 1: Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks. arm 2: Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.

Interventions: intervention 1: Nateglinide 120 mg intervention 2: Acarbose 50 mg
Intervention descriptions: intervention 1: Nateglinide 120 mg was supplied as tablets. intervention 2: Acarbose 50 mg was supplied as tablets.

Protocol document: